Stock Events

Stock Events

Eupraxia Pharmaceuticals 

C$10.31
14
+C$0.27+2.69% Today

Statistics

Day High
10.58
Day Low
10.17
52W High
12.86
52W Low
3.96
Volume
72,301
Avg. Volume
88,608
Mkt Cap
521.67M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.42
-0.34
-0.26
-0.17
Expected EPS
-0.2634898558564896
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-71.91MNet Income

Analyst Ratings

$16.37Average Price Target
The highest estimate is 20.74.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EPRX.TO. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the pharmaceuticals sector, focusing on immunology and oncology, areas Eupraxia also targets with its drug development.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global biopharmaceutical company with a broad range of products in various therapeutic areas, overlapping with Eupraxia's focus.
Merck
MRK
Mkt Cap214.76B
Merck operates in the pharmaceuticals industry, developing drugs that could directly compete with Eupraxia's pipeline in areas like inflammation and pain management.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment, competes across various therapeutic areas, including those being targeted by Eupraxia.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb offers a wide range of pharmaceutical products, potentially competing with Eupraxia in the development of treatments for chronic conditions.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that operates in similar therapeutic areas as Eupraxia, making it a direct competitor in drug development.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences focuses on areas like inflammation and oncology, directly competing with Eupraxia's research and development efforts.
AMGEN
AMGN
Mkt Cap160.66B
Amgen specializes in biopharmaceuticals, with a product lineup that could compete with Eupraxia's treatments in development.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in biopharmaceuticals, focusing on innovative treatments that could rival Eupraxia's pipeline.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals engages in creating new therapies for treating chronic diseases, a field where Eupraxia is also aiming to innovate.

About

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Show more...
CEO
Dr. James A. Helliwell FRCPC, M.D.
Employees
33
Country
CA
ISIN
CA29842P1053

Listings

F
DE
X43.F
TO
CA
EPRX.TO
XNAS
US
EPRX
TO
CA
EPRX-WTA.TO

0 Comments

Share your thoughts

FAQ

What is Eupraxia Pharmaceuticals stock price today?▼
The current price of EPRX.TO is C$10.31 CAD — it has increased by +2.69% in the past 24 hours. Watch Eupraxia Pharmaceuticals stock price performance more closely on the chart.
What is Eupraxia Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Eupraxia Pharmaceuticals stocks are traded under the ticker EPRX.TO.
Is Eupraxia Pharmaceuticals stock price growing?▼
EPRX.TO stock has risen by +5.31% compared to the previous week, the month change is a -7.45% fall, over the last year Eupraxia Pharmaceuticals has showed a +119.36% increase.
What is Eupraxia Pharmaceuticals market cap?▼
Today Eupraxia Pharmaceuticals has the market capitalization of 521.67M
When is the next Eupraxia Pharmaceuticals earnings date?▼
Eupraxia Pharmaceuticals is going to release the next earnings report on May 07, 2026.
What were Eupraxia Pharmaceuticals earnings last quarter?▼
EPRX.TO earnings for the last quarter are -0.42 CAD per share, whereas the estimation was -0.21 CAD resulting in a -103.85% surprise. The estimated earnings for the next quarter are N/A CAD per share.
What is Eupraxia Pharmaceuticals revenue for the last year?▼
Eupraxia Pharmaceuticals revenue for the last year amounts to 0 CAD.
What is Eupraxia Pharmaceuticals net income for the last year?▼
EPRX.TO net income for the last year is -71.91M CAD.
How many employees does Eupraxia Pharmaceuticals have?▼
As of April 01, 2026, the company has 33 employees.
In which sector is Eupraxia Pharmaceuticals located?▼
Eupraxia Pharmaceuticals operates in the Health Care sector.
When did Eupraxia Pharmaceuticals complete a stock split?▼
Eupraxia Pharmaceuticals has not had any recent stock splits.
Where is Eupraxia Pharmaceuticals headquartered?▼
Eupraxia Pharmaceuticals is headquartered in Victoria, CA.